These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1817333)

  • 1. [Effects of erythropoietin on the cardiovascular system and the intradialytic hemodynamic behavior].
    Quarello F; Martina G; Beltrame G; Boero R; Forneris G; Borca M; Iadarola GM; Stramignoni E; Maffei S; Piccoli G
    Minerva Urol Nefrol; 1991; 43(3):125-30. PubMed ID: 1817333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin.
    Fellner SK; Lang RM; Neumann A; Korcarz C; Borow KM
    Kidney Int; 1993 Dec; 44(6):1309-15. PubMed ID: 8301932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients.
    Tomczak-Watras W; Strózecki P; Zuchora Z; Szefer J; Manitius J
    Pol Arch Med Wewn; 2009; 119(1-2):45-51. PubMed ID: 19341178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
    Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
    Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis.
    Pascual J; Teruel JL; Marcén R; Liaño F; Moya JL; Jiménez M; Ortuño J
    Int J Artif Organs; 1992 Jun; 15(6):349-53. PubMed ID: 1639526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study.
    Pascual J; Teruel JL; Moya JL; Liaño F; Jiménez-Mena M; Ortuño J
    Clin Nephrol; 1991 Jun; 35(6):280-7. PubMed ID: 1831414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure.
    Hand MF; Haynes WG; Johnstone HA; Anderton JL; Webb DJ
    Kidney Int; 1995 Sep; 48(3):806-13. PubMed ID: 7474668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.
    London GM; Zins B; Pannier B; Naret C; Berthelot JM; Jacquot C; Safar M; Drueke TB
    Kidney Int; 1989 Nov; 36(5):878-82. PubMed ID: 2615194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
    Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
    Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients.
    Robertson HT; Haley NR; Guthrie M; Cardenas D; Eschbach JW; Adamson JW
    Am J Kidney Dis; 1990 Apr; 15(4):325-32. PubMed ID: 2321645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
    Sapojnikov M; Veksler A; Yagil Y; Kogan J; Turkot S; Boris G; Oren S
    Ren Fail; 2005; 27(2):199-203. PubMed ID: 15807186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance.
    Pappas KD; Gouva CD; Katopodis KP; Nikolopoulos PM; Korantzopoulos PG; Michalis LK; Goudevenos JA; Siamopoulos KC
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):37-44. PubMed ID: 18095148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin and its effects on macro- and microcirculation during normovolemia. A physiological study of hemodynamics, fluid status and skin microcirculation.
    Wirtz JJ; Leunissen KM; van Esser JW; Cheriex EC; Slaaf DW; Reneman RS; van Hooff JP
    Blood Purif; 1990; 8(5):285-94. PubMed ID: 2091688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.
    Hampl H; Hennig L; Rosenberger C; Amirkhalily M; Gogoll L; Riedel E; Scherhag A
    Am J Nephrol; 2005; 25(3):211-20. PubMed ID: 15900093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
    Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.